Highlights and Quick Summary
- EBIT for the quarter ending March 31, 2022 was $-18.2 Million (a -43.19% decrease compared to previous quarter)
- Year-over-year quarterly EBIT decreased by -13.42%
- Annual EBIT for 2021 was $-215 Million (a 26.05% increase from previous year)
- Annual EBIT for 2020 was $-170 Million (a 86.29% increase from previous year)
- Annual EBIT for 2019 was $-91.4 Million (a 92.82% increase from previous year)
- Twelve month EBIT ending March 31, 2022 was $-99.9 Million (a -6.91% decrease compared to previous quarter)
- Twelve month trailing EBIT increased by 7.27% year-over-year
Trailing EBIT for the last four month:
31 Mar '22 | 31 Dec '21 | 30 Sep '21 | 30 Jun '21 |
---|---|---|---|
$-99.9 Million | $-107 Million | $-101 Million | $-93.2 Million |
Visit stockrow.com/PHAS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBIT of PhaseBio Pharmaceuticals
Most recent EBITof PHAS including historical data for past 10 years.Interactive Chart of EBIT of PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals EBIT for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2022 | $-18.23 | – | – | – | – |
2021 | $-32.09 | $-28.58 | $-21.05 | $-25.65 | $-214.72 |
2020 | $-25.98 | $-20.49 | $-24.1 | $-14.29 | $-170.35 |
2019 | $-11.28 | $-11.59 | $-9.48 | $-7.38 | $-91.44 |
2018 | $-7.66 | $-5.0 | $-4.11 | $-2.88 | $-47.42 |
2017 | – | – | – | $-1.9 | $-23.48 |
2016 | – | – | – | – | $-19.0 |
Business Profile of PhaseBio Pharmaceuticals
Sector: Healthcare
Industry: Biotechnology